A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The adverse metabolic consequences of obesity are best predicted by the quantity of visceral fat. Excess glucocorticoids produce visceral obesity and diabetes, but circulating glucocorticoid levels are normal in typical obesity. Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11β hydroxysteroid dehydrogenase type 1 (11β HSD-1). We created transgenic mice overexpressing 11β HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans. These mice had increased adipose levels of corticosterone and developed visceral obesity that was exaggerated by a high-fat diet. The mice also exhibited pronounced insulin-resistant diabetes, hyperlipidemia, and, surprisingly, hyperphagia despite hyperleptinemia. Increased adipocyte 11β HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“other health outcomes associated with better quality of life improved, including sleep apnoea136 and mobility137.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [137]
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., & Lodish, H. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26746 · Cited by 3,237
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Self-citationSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citationThe Degree of Masculine Differentiation of Obesities
VAGUE, J. (1956) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/4.1.20 · Cited by 1,410
Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
Abel, E. D., Peroni, O., Kim, J. K., Kim, Y.-B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., & Kahn, B. B. (2001) · Nature · doi:10.1038/35055575 · Cited by 1,253
Frühbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e827 · Cited by 974
Research works printed but not linked: 5
- 10.1210/jcem.86.3.7453 · doi:10.1210/jcem.86.3.7453 · Paper page
- 10.1101/gad.7.7b.1318 · doi:10.1101/gad.7.7b.1318 · Paper page
- Supplementary data are available on Science Online at www.sciencemag.org/cgi/content/full/294/5549/2166/DC1.
- Strack A. M., Bradbury M. J., Dallman M. F., Am. J. Physiol. 268, R183 (1995).
- 10.1210/jcem.83.5.4951 · doi:10.1210/jcem.83.5.4951 · Paper page
Cited by
Items 401–500 of 1,003
Mineralocorticoid receptors in the metabolic syndrome
Zennaro, M., Caprio, M., & Fève, B. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.05.006 · Cited by 88
Chapman, K. E., Coutinho, A. E., Gray, M., Gilmour, J. S., Savill, J., & Seckl, J. R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1366.030 · Cited by 89
Self-citationChen, C., Xu, Y. J., Guo, Z., Yang, J., Wu, M., & Hu, X. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-108 · Cited by 89
“dehy-drogenase type 1(11βHSD-1) excessively expressed in fat cells, it would cause visceral adiposity and a series of metabolic disorders, which indicates that 11βHSD- 1 enzyme may have the same molecular basis with visceral obesity and metabolic disorders [30].”
BackgroundKrishna, S., Lin, Z., Serre, C. B. D. L., Wagner, J. J., Harn, D. A., Pepples, L. M., Djani, D. M., Weber, M., Srivastava, L., & Filipov, N. M. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.007 · Cited by 89
Diet‐induced central obesity and insulin resistance in rabbits
Zhao, S., Chu, Y., Zhang, C., Lin, Y., Xu, K., Yang, P., Fan, J., & Liu, E. (2007) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/j.1439-0396.2007.00723.x · Cited by 88
“So far, diet-induced, spontaneous and transgenic rodents have been used as a model of MS (Masuzaki et al., 2001; Hiraoka-Yamamoto et al., 2004; Diniz et al., 2005; Lerman et al., 2005; Kagota et al., 2006; Russell and Proctor, 2006) and they are useful for the study of pathophysiological processes of MS.”
MethodEffects of glucocorticoids on leptin levels and eating behaviour in women
Uddén, J., Björntorp, P., Arner, P., Barkeling, B., Meurling, L., & Rössner, S. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01099.x · Cited by 75
Mojiminiyi, O. A., & Abdella, N. A. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601032532 · Cited by 82
Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men
Johnstone, A., Faber, P., Andrew, R., Gibney, E., Elia, M., Lobley, G., Stubbs, R., & Walker, B. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500185 · Cited by 79
“In contrast, mice with transgenic overexpression of 11HSD1 under the adipose-specific AP2 promoter have central obesity and its metabolic complications (hyperglycaemia, increased free fatty acids, insulin resistance) ( 16 ).”
BackgroundDiabetes Mellitus Secondary to Cushing’s Disease
Barbot, M., Ceccato, F., & Scaroni, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00284 · Cited by 75
“The overexpression of 11 β HSD1 in adipose tissue is correlated with the development of insulin resistance and obesity (22).”
BackgroundUnderstanding adipose tissue development from transgenic animal models
Valet, P., Tavernier, G., Castan‐Laurell, I., Saulnier‐Blache, J. S., & Langin, D. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30458-2 · Cited by 88
Lavery, G. G., Zielinska, A. E., Gathercole, L. L., Hughes, B., Semjonous, N., Guest, P., Saqib, K., Sherlock, M., Reynolds, G., Morgan, S. A., et al. (2012) · Endocrinology · doi:10.1210/en.2012-1019 · Cited by 69
Disruption of glucocorticoid action by environmental chemicals: Potential mechanisms and relevance
Odermatt, A., Gumy, C., Atanasov, A. G., & Dzyakanchuk, A. A. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.010 · Cited by 88
Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome
Mariniello, B., Ronconi, V., Rilli, S., Bernante, P., Boscaro, M., Mantero, F., & Giacchetti, G. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02228 · Cited by 74
“Transgenic mice overexpressing HSD11B1 selectively in adipose tissue are obese, hypertensive, dyslipidaemic and insulin-resistant ( 7 ), while transgenic mice overexpressing HSD11B1 selectively in liver do not exhibit obesity, but display insulin resistance, fatty liver, dyslipidaemia and hypertension (24).”
BackgroundBohlooly-Y, M., Olsson, B., Bruder, C. E. G., Lindén, D., Sjögren, K., Bjursell, M., Egecioglu, E., Svensson, L., Brodin, P., Waterton, J. C., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.1.51 · Cited by 83
“Glucocorticoid treatment has been shown to increase food intake in humans (74) and mice (53) and promote fat accumulation and insulin resistance in mice (75,76).”
BackgroundAdiponectin is stimulated by adrenalectomy inob/obmice and is highly correlated with resistin mRNA
Makimura, H., Mizuno, T. M., Bergen, H., & Mobbs, C. V. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00227.2002 · Cited by 87
“(17) have shown that transgenic mice overexpressing the 11 -hydroxysteroid dehydrogenase type 1 gene exhibit elevated local levels of corticosterone in adipose tissue and subsequently have lower adiponectin expression (17).”
BackgroundHult, G. T. M., Elleby, B., Shafqat, N., Svensson, S., Rane, A., J�rnvall, H., Abrahmsén, L., & Oppermann, U. C. T. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3476-y · Cited by 86
Depot‐specific Regulation of the Conversion of Cortisone to Cortisol in Human Adipose Tissue
Lee, M., Fried, S. K., Mundt, S. S., Wang, Y., Sullivan, S., Stefanni, A., Daugherty, B. L., & Hermanowski‐Vosatka, A. (2008) · Obesity · doi:10.1038/oby.2008.207 · Cited by 73
Newell, F., Su, H., Tornqvist, H. E., Whitehead, J. P., Prins, J. B., & Hutley, L. J. (2006) · The FASEB Journal · doi:10.1096/fj.05-5710fje · Cited by 86
“Epidemiological evidence strongly correlates intra-abdominal, or visceral, adiposity with the metabolic and cardiovascular complications that accompany obesity (31).”
Véniant, M. M., Hale, C., Hungate, R. W., Gahm, K. H., Emery, M. G., Jona, J. A., Joseph, S., Adams, J., Hague, A. B., Moniz, G. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100242d · Cited by 85
Weber-Hamann, B., Kratzsch, J., Kopf, D., Lederbogen, F., Gilles, M., Heuser, I., & Deuschle, M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.002 · Cited by 85
“Local mechanisms are thought to be involved, such as an elevation of the activity of the enzyme 11b-hydroxysteroid dehydrogenase type 1 in visceral adipocytes, increasing the local production of cortisol concentrations and resulting in an increased proliferation and differentiation of the visceral fat cell (Masuzaki e…”
BackgroundComparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species
Arampatzis, S., Kadereit, B., Schuster, D., Balazs, Z., Schweizer, R. A. S., Frey, F. J., Langer, T., & Odermatt, A. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01736 · Cited by 76
“…elevated adipose corticosterone concentrations and are susceptible to insulin-resistant diabetes, hyperlipidemia and high arterial blood pressure due to increased sensitivity to dietary salt and increased plasma levels of angiotensinogen, angiotensin II and aldosterone (Masuzaki et al. 2001, 2003).”
Rohde, J. J., Pliushchev, M. A., Sorensen, B. K., Wódka, D., Shuai, Q., Wang, J., Fung, S., Monzon, K., Chiou, W. J. H., Pan, L., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0609364 · Cited by 85
Ortiz, R., Kluwe, B., Odei, J. B., Echouffo Tcheugui, J. B., Sims, M., Kalyani, R. R., Bertoni, A. G., Golden, S. H., & Joseph, J. J. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.12.237 · Cited by 76
“Animal studies have shown that overexpression of 11β-HSD1 yields lower serum, but higher adipocyte corticosterone (Incollingo Rodriguez et al., 2015; Masuzaki et al., 2001), which could then yield higher levels of active cortisol and impact adipocyte insulin resistance.”
BackgroundGurnell, M. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.10.001 · Cited by 84
11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents
Boyle, C. D., & Kowalski, T. J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902967658 · Cited by 74
“Transgenic overexpression of 11β-HSD1 in adipose tissue of mice produces intra-abdominal obesity, insulin resistance, dyslipidemia and hypertension [32-34] in the absence of elevated corticosterone, whereas mice with targeted disruption of the 11β-HSD1 gene are resistant to diet-induced obesity [35], and display impro…”
Patsouris, D., Neels, J. G., Fan, W., Li, P.-P., Nguyen, M. T. A., & Olefsky, J. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041665 · Cited by 84
Wulsin, L. R., Herman, J. P., & Thayer, J. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.12.010 · Cited by 83
A meta-analysis of quantitative trait loci associated with body weight and adiposity in mice
Wuschke, S., Dahm, S., Schmidt, C., Joost, H., & Al‐Hasani, H. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803473 · Cited by 83
Agouti Expression in Human Adipose Tissue
Smith, S. R., Gawronska-Kozak, B., Janderová, L., Nguyen, T., Murrell, A., Stephens, J. M., & Mynatt, R. L. (2003) · Diabetes · doi:10.2337/diabetes.52.12.2914 · Cited by 72
“11 -HSD-1 causes visceral obesity when overexpressed in transgenic mice (42), but this effect is unlikely to be due to the upregulation of agouti, as murine adipose tissue does not express agouti.”
BackgroundTerao, M., Murota, H., Kimura, A., Kato, A., Ishikawa, A., Igawa, K., Miyoshi, E., & Katayama, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025039 · Cited by 77
“model metabolic syndrome [13,14].”
PPARγ as a metabolic regulator: insights from genomics and pharmacology
Savage, D. B. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405008793 · Cited by 82
Jacobson, P. B., von Geldern, T. W., Öhman, L., Osterland, M., Wang, J., Zinker, B. A., Wilcox, D. M., Nguyen, P., Mika, A. K., Fung, S., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081257 · Cited by 82
Zhang, J., Osslund, T. D., Plant, M., Clogston, C. L., Nybo, R. E., Xiong, F., Delaney, J. M., & Jordan, S. R. (2005) · Biochemistry · doi:10.1021/bi047599q · Cited by 82
Tomlinson, J., & Stewart, P. M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0023 · Cited by 82
“and transgenic mice overexpressing 11β-HSD1 specifically within adipose tissue are centrally obese with enlarged fat cells”
BackgroundRole of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Pοlyzos, S. A., & Targher, G. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00556-1 · Cited by 81
“11β-HSD1 over-expression in the adipose tissue of transgenic nonobese mice results in dyslipidemia and hepatic steatosis [39], whereas 11β-HSD1 over-expression in the liver results in more severe IR and MASLD [40]; this implies that some GC-induced effects on MASLD are not mediated by obesity.”
Baudrand, R. F., Carvajal, C. A., Riquelme, A. J., Morales, M., Solís, N., Pizarro, M., Escalona, A., Boza, C., Pérez, G., Domínguez, A., et al. (2009) · Obesity Surgery · doi:10.1007/s11695-009-9937-0 · Cited by 81
“Selective overexpression of 11β-HSD1 in adipose tissue is associated to visceral obesity, pronounced insulin-resistant diabetes, and dyslipidemia [16].”
BackgroundNuotio-Antar, A. M., Hachey, D. L., & Hasty, A. H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00522.2007 · Cited by 81
“It has been proposed that a resulting increased flux of glucocorticoids regenerated by visceral adipose tissue enters the portal circulation, impacting glucocorticoid-mediated events at sites within the splanchnic bed (3, 30).”
BackgroundMedvedev, K. E., Kinch, L. N., Schaeffer, R. D., & Grishin, N. V. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007569 · Cited by 73
“The therapeutic potential of 11-HSD1 inhibition has been shown previously [86].”
BackgroundNyirenda, M. J., Carter, R., Tang, J. I., de Vries, A., Schlumbohm, C., Hillier, S. G., Streit, F., Oellerich, M., Armstrong, V. W., Fuchs, E., et al. (2009) · Diabetes · doi:10.2337/db09-0873 · Cited by 70
“Transgenic overexpression of 11 -HSD1 selectively in adipose tissue in mice recapitulates all the major features of metabolic syndrome without changes in circulating steroid levels (12), whereas overexpression of 11 -HSD1 in liver alone produces an attenuated syndrome with insulin resistance, dyslipidemia, and hyperte…”
BackgroundSelf-citationLukaszewski, M.-A., Mayeur, S., Fajardy, I., Delahaye, F., Dutriez-Casteloot, I., Montel, V., Dickes-Coopman, A., Laborie, C., Lesage, J., Vieau, D., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00011.2011 · Cited by 69
“In mice, overexpression of 11 HSD1 in adipose tissue resulted in visceral obesity (39) when fed under HF diet, whereas adipose tissue overexpression of 11 -HSD2 protects mice from HF diet-induced obesity (33).”
BackgroundAuvinen, H. E., Romijn, J. A., Biermasz, N. R., Pijl, H., Havekes, L. M., Smit, J. W. A., Rensen, P. C. N., & Pereira, A. M. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0056 · Cited by 62
“…of cortisol exposure at the tissue level in mice, through stimulation or abrogation of 11b-hydroxysteroid dehydrogenase type-1 and -2 (11b-HSD-1 and -2) activity can increase or regress visceral fat accumulation, as well as other features of the MetS (Masuzaki et al. 2001, Cooper & Stewart 2009).”
BackgroundAdrenocortical activity in healthy children is associated with fat mass
Dimitriou, T., Maser‐Gluth, C., & Remer, T. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.3.731 · Cited by 80
Ooi, L. Y., Walker, B. R., Bodkin, P. A., & Whittle, I. R. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690701827340 · Cited by 80
Increased expression of 11β‐hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes
Abdallah, B. M., Beck‐Nielsen, H., & Gaster, M. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01552.x · Cited by 69
Liu, T., Wang, J., Tong, Y., Wu, L., Xie, Y., He, P., Lin, S., & Hu, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04840-x · Cited by 80
“Conversely, overexpression of HSD11B1 (corticosteroid 11-beta-dehydrogenase isozyme 1), which catalyzes the conversion of the active form of cortisol [74], has been found to result in visceral obesity, insulin-resistant diabetes, and dyslipidemia [75].”
BackgroundRelationship between stress, inflammation and metabolism
Seematter, G., Binnert, C., Martin, J.-L., & Tappy, L. (2004) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200403000-00011 · Cited by 70
Yam, K. Y., Naninck, E. F. G., Abbink, M. R., la Fleur, S. E., Schipper, L., van den Beukel, J. C., Grefhorst, A., Oosting, A., van der Beek, E. M., Lucassen, P. J., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.12.012 · Cited by 78
Hu, G., Lin, H., Lian, Q., Zhou, S., Guo, J., Zhou, H.-Y., Chu, Y., & Ge, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0049976 · Cited by 78
“It is true that overexpression of 11b-HSD1 gene (Hsd11b1) in the fat tissue of mice caused central obesity, disturbed lipid profiles and insulin resistance [3].”
Background11 β ‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus
Hollis, G., & Huber, R. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01305.x · Cited by 72
“These mice exhibit a phenotype closely resembling that of human metabolic syndrome including visceral obesity, insulin resistance, hyperlipidaemia, hyperphagia and hypertension [15,16].”
BackgroundLiu, C., Feng, T., Zhu, N., Liu, P., Han, X., Chen, M., Xiao, W., Li, N., Li, Y., Xu, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep09530 · Cited by 78
Eckel, R. H. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005320 · Cited by 78
“Murine examples of the impact of body fat distribution on insulin resistance and the metabolic syndrome include mice with over-expression of 11-hydroxysteroid dehydrogenase 1 that have elevated intra-adipose corticosterone levels but normal circulating corticosterone levels (Masuzaki et al. 2001).”
BackgroundShen, Y., Roh, H. C., Kumari, M., & Rosen, E. D. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.013 · Cited by 70
“In mice, administration of GCs causes metabolic dysfunction that is highly reminiscent of that seen in human studies and transgenic overexpression of 11bhydroxysteroid dehydrogenase 1 (11b-HSD1) in fat, which increases active GC levels and leads to increased adipose tissue mass, insulin resistance, and diabetes [12].”
BackgroundShin, J., Toyoda, S., Nishitani, S., Fukuhara, A., Kita, S., Otsuki, M., & Shimomura, I. (2021) · Diabetes · doi:10.2337/db20-1094 · Cited by 77
Di Pietro, N., Panel, V., Hayes, S., Bagattin, A., Meruvu, S., Pandolfi, A., Hugendubler, L., Fejes-Tóth, G., Naray-Fejes-Tóth, A., & Mueller, E. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0265 · Cited by 73
Alberti, L., Girola, A., Gilardini, L., Conti, A., Cattaldo, S., Micheletto, G., & Invitti, C. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803677 · Cited by 77
Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy
Tobin, J. F., & Freedman, L. P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.07.004 · Cited by 77
Balamurugan, R., Dekker, F. J., & Waldmann, H. (2005) · Molecular BioSystems · doi:10.1039/b503623b · Cited by 70
Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview
Varga, O., Harangi, M., Olsson, I. A. S., & Hansen, A. K. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00667.x · Cited by 75
“the specific quantity of visceral fat (139).”
An animal model of spontaneous metabolic syndrome: Nile grass rat
Noda, K., Melhorn, M. I., Zandi, S., Frimmel, S., Tayyari, F., Hisatomi, T., Almulki, L., Prończuk, A., Hayes, K. C., & Hafezi‐Moghadam, A. (2010) · The FASEB Journal · doi:10.1096/fj.09-152678 · Cited by 76
McNelis, J. C., Manolopoulos, K. N., Gathercole, L. L., Bujalska, I. J., Stewart, P. M., Tomlinson, J. W., & Arlt, W. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00314.2012 · Cited by 66
17β-Hydroxysteroid Dehydrogenase Type XI Localizes to Human Steroidogenic Cells
Chai, Z., Brereton, P., Suzuki, T., Sasano, H., Obeyesekere, V., Escher, G., Saffery, R., Fuller, P., Enriquez, C., & Krozowski, Z. (2003) · Endocrinology · doi:10.1210/en.2002-221030 · Cited by 64
Gambineri, A., Vicennati, V., Genghini, S., Tomassoni, F., Pagotto, U., Pasquali, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2222 · Cited by 75
“11 -HSD1 seems to be important in metabolic disease, because in mice, increasing enzyme activity in adipose tissue enhances local glucocorticoid levels and produces a metabolic syndrome (3), whereas decreasing enzyme activity protects against obesity and the metabolic syndrome (4, 5).”
BackgroundObesity and diabetes in transgenic mice expressing proSAAS
Wei, S., Feng, Y., Che, F.-Y., Pan, H., Mzhavia, N., Devi, L. A., McKinzie, A., Levin, N. W., Richards, W. G., & Fricker, L. D. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800357 · Cited by 75
“In addition to the various peptides, other gene products have been implicated in body weight regulation from studies involving transgenic mice, knock-out mice, or mice with naturally-occurring mutations; examples include various receptors (Chen et al. 1996, Huszar et al. 1997, Chen et al. 2000, Marsh et al. 2002), sec…”
Perrone, C. E., Mattocks, D. A. L., Hristopoulos, G., Plummer, J. D., Krajcik, R. A., & Orentreich, N. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700194-jlr200 · Cited by 68
“Despite extensive evidence demonstrating that high AT 11β-HSD1 activity correlates positively with visceral adiposity and metabolic syndrome in both humans and laboratory animals (16,18,46-49), this study showed an inverse relationship between 11βHSD1 activity levels and adipocyte size.”
BackgroundMueller, K. M., Hartmann, K., Kaltenecker, D., Vettorazzi, S., Bauer, M., Mauser, L., Amann, S., Jall, S., Fischer, K., Esterbauer, H., et al. (2017) · Diabetes · doi:10.2337/db16-0381 · Cited by 66
“In mice and humans, an increase in GC regeneration by the enzyme 11β-HSD1 within WAT compartments suggests a role of the GC-GR axis in common obesity (2; 12-16).”
BackgroundMorton, N. M., Densmore, V., Wamil, M., Ramage, L., Nichol, K., Bünger, L., Seckl, J. R., & Kenyon, C. J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3371 · Cited by 66
“Although it is abundantly clear that aberrantly elevated adipose 11 -HSD-1 can drive a complete metabolic syndrome in mice (7,17) and potentially contributes to it in humans (13–15), there is a precedent for obesity with low FIG.”
BackgroundResultInfluentialSelf-citationSex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity
Pasquali, R., Vicennati, V, Gambineri, A., & Pagotto, U. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.129 · Cited by 74
Baziar, N., & Parohan, M. (2019) · Phytotherapy Research · doi:10.1002/ptr.6542 · Cited by 74
Weidner, C., Wowro, S. J., Freiwald, A., Kawamoto, K., Witzke, A., Kliem, M., Siems, K., Müller‐Kuhrt, L., Schroeder, F. C., & Sauer, S. (2013) · Diabetologia · doi:10.1007/s00125-013-2920-2 · Cited by 74
“In contrast to RGZ, amorfrutin B further showed reduced RNA expression of the cortisol generating hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1), which is linked to central obesity [12].”
BackgroundHoffman, D. J., Martins, P., Roberts, S. B., & Sawaya, A. L. (2007) · Nutrition · doi:10.1016/j.nut.2007.06.006 · Cited by 74
Molusky, M. M., Li, S., Ma, D., Yu, L., & Lin, J. D. (2012) · Diabetes · doi:10.2337/db11-0970 · Cited by 65
“Tissue-specific activation of glucocorticoid signaling by transgenic expression of HSD1 leads to the development of key features of metabolic syndrome, including central obesity, glucose intolerance, and hypertension (15,16).”
BackgroundUpdated survey of the steroid-converting enzymes in human adipose tissues
Tchernof, A., Mansour, M. F., Pelletier, M., Boulet, M.-M., Nadeau, M., & Luu-The, V. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.11.011 · Cited by 73
“and non-esterified fatty acid release are also increased in this model [27].”
Visceral adiposity, inflammation, and hippocampal function in obesity
Stranahan, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108920 · Cited by 74
Novel targets and therapeutic strategies for type 2 diabetes
Morral, N. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(03)00031-6 · Cited by 73
Dzyakanchuk, A. A., Balázs, Z., Nashev, L. G., Amrein, K. E., & Odermatt, A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.009 · Cited by 73
Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases
Beseda, I., Czollner, L., Shah, P., Khunt, R. C., Gaware, R., Kosma, P., Stanetty, C., Ruiz-Ruiz, M. C. D., Amer, H., Mereiter, K., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.036 · Cited by 73
Smith, S. (2003) · Biochimie · doi:10.1016/j.biochi.2003.10.010 · Cited by 73
Evidence That the 11 β-Hydroxysteroid Dehydrogenase (11 β-HSD1) Is Regulated by Pentose Pathway Flux
McCormick, K. L., Wang, X., & Mick, G. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506026200 · Cited by 72
11β-Hydroxysteroid dehydrogenase: unexpected connections
Walker, E. A., & Stewart, P. M. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00134-6 · Cited by 72
Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?
MacLeod, C., Hadoke, P. W. F., & Nixon, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147622 · Cited by 72
“, in the liver [28] or central adipose tissue [29]) without elevated circulating levels of the steroid.”
BackgroundMCH−/− Mice Are Resistant to Aging-Associated Increases in Body Weight and Insulin Resistance
Jeon, J. Y., Bradley, R. L., Kokkotou, E. G., Marino, F. E., Wang, X., Pissios, P., & Maratos-Flier, E. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-0203 · Cited by 65
Cortisol dysregulation in obesity-related metabolic disorders
Baudrand, R. F., & Vaidya, A. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000152 · Cited by 72
“[33] developed a rodent model with selective 11b-HSD1 overexpression in adipose tissue, leading to visceral obesity, diabetes, and dyslipidemia.”
BackgroundIdiopathic intracranial hypertension, hormones, and 11ß-hydroxysteroid dehydrogenases
Sinclair, A. J., Markey, K. A., Uldall, M., Cato, L. D., Miah, M. S., Botfield, H. F., Gonzalez, A. M., Jensen, R., & Hassan‐Smith, G. (2016) · Journal of Pain Research · doi:10.2147/jpr.s80824 · Cited by 72
“71 This suggests a role for adipose-derived 11 β - HSD1 in the development of a metabolic syndrome.”
Dekker, F. J., Koch, М. A., & Waldmann, H. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.03.003 · Cited by 72
Mineralocorticoid receptor activation in obesity hypertension
Nagase, M., & Fujita, T. (2009) · Hypertension Research · doi:10.1038/hr.2009.86 · Cited by 72
Bujalska, I. J., Walker, E. A., Tomlinson, J. W., Hewison, M., & Stewart, P. M. (2002) · Endocrine Research · doi:10.1081/erc-120016822 · Cited by 66
“Recently, convincing data on the pivotal role of 11b-HSD1 in development of visceral obesity and metabolic syndrome have been published.([20]) Over expression of 11b-HSD1 enzyme in adipose tissue produced 3-fold higher local concentration of corticosterone in mesenchymal adipose tissue despite normal serum glucocortic…”
Franks, P. W., Knowler, W. C., Nair, S., Koska, J., Lee, Y.-H., Lindsay, R. S., Walker, B. R., Looker, H. C., Permana, P. A., Tataranni, P. A., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000144294.28985.d5 · Cited by 59
PASSCLAIM1?Body weight regulation, insulin sensitivity and diabetes risk
Riccardi, G., Aggett, P. J., Brighenti, F., Delzenne, N. M., Frayn, K. N., Nieuwenhuizen, A. G., Pannemans, D. L. E., Theis, S., Tuijtelaars, S., & Vessby, B. O. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-1202-7 · Cited by 72
Miyawaki, T., Abe, M., Yahata, K., Kajiyama, N., Katsuma, H., & SAITO, N. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.1138 · Cited by 69
Adipose tissue as source and target for novel therapies
Klein, J. C., Perwitz, N., Kraus, D., & Faßhauer, M. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.11.008 · Cited by 70
Hughes, K. A., Manolopoulos, K. N., Iqbal, J., Cruden, N. L., Stimson, R. H., Reynolds, R. M., Newby, D. E., Andrew, R., Karpe, F., & Walker, B. R. (2012) · Diabetes · doi:10.2337/db11-1345 · Cited by 64
“Adipose tissue 11bHSD1 has been a focus of research since the description of its upregulation in human obesity (7) and the potent effects of its manipulation in mice (47), but it has been assumed to be an exclusive 11b-reductase.”
BackgroundRasche, A., Al‐Hasani, H., & Herwig, R. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-310 · Cited by 69
“Hsd11b1 is increased in obese subjects and transgenic mice over-expressing Hsd11b1 develop visceral obesity [40].”
BackgroundWan, Z., Chenail, E., Xiang, J. S., Li, H., Ipek, M., Bard, J., Svenson, K., Mansour, T. S., Xu, X., Tian, X., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900639u · Cited by 69
Adipose Tissue and Ceramide Biosynthesis in the Pathogenesis of Obesity
Samad, F., Badeanlou, L., Shah, C., & Yang, G. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0650-1_5 · Cited by 69
Obesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
“Transgenic mice with increased 11β-HSD1 activity have an excess of visceral fat and are insulin resistant, diabetic, and dyslipidemic (Masuzaki et al., 2001).”
BackgroundNixon, M., Wake, D. J., Livingstone, D. E. W., Stimson, R. H., Esteves, C. L., Seckl, J. R., Chapman, K. E., Andrew, R., & Walker, B. R. (2012) · Diabetes · doi:10.2337/db11-0931 · Cited by 69
“In genetically modified mice, overexpression of 11b-HSD1 in adipose tissue (18) or liver (19) results in increased glucocorticoid action and insulin resistance, whereas targeted disruption of Hsd11b1 protects against insulin resistance and central obesity on high-fat feeding (20–22).”
BackgroundSelf-citationWamil, M., Battle, J. H., Turban, S., Kipari, T., Seguret, D., de Sousa Peixoto, R., Nelson, Y. B., Nowakowska, D., Ferenbach, D., Ramage, L., et al. (2011) · Diabetes · doi:10.2337/db10-0830 · Cited by 57
“Conversely, visceral fat expresses higher levels of the glucocorticoid receptor (2,5,6), which may contribute to its reduced insulin sensitivity and exaggerated expansion in response to increased plasma cortisol (Cushing’s syndrome) or adipose 11b-HSD1 (idiopathic obesity).”
BackgroundSelf-citationNutrition, Glucocorticoids and Pancreas Development
Bréant, B., Gesina, E., & Blondeau, B. (2006) · Hormone Research in Paediatrics · doi:10.1159/000091513 · Cited by 61
“Furthermore, it has been recently shown that increased glucocorticoid production in adipose tissue leads to visceral obesity and insulin-resistant diabetes in mice [”
BackgroundSwali, A., Walker, E. A., Lavery, G. G., Tomlinson, J., & Stewart, P. M. (2008) · Diabetologia · doi:10.1007/s00125-008-1137-2 · Cited by 69
“Tissue-specific overexpression models in liver and adipose tissue have highlighted potentially important roles in the control of adiposity, carbohydrate metabolism and insulin sensitivity [18–20].”
Neuroendocrine and metabolic effects of adipocyte-derived hormones
Jackson, M. B., & Ahima, R. S. (2006) · Clinical Science · doi:10.1042/cs20050243 · Cited by 68
Metadata
- Authors
- Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University of Edinburgh (GB)
- Corresponding author
- Flier, Jeffrey S.
- Venue
- Science
- Published
- 2001-12-07
- Volume
- 294
- Issue
- 5549
- Pages
- 2166-2170
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2117268230
- Cited by
- 1,766
- References
- 34
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 30 · 2023: 19 · 2022: 23 · 2021: 44 · 2020: 34 · 2019: 39 · 2018: 54 · 2017: 52 · 2016: 63 · 2015: 74 · 2014: 72 · 2013: 106 · 2012: 98
- FWCI
- 71.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- visceral obesity, metabolic syndrome, 11β-hydroxysteroid dehydrogenase type 1, glucocorticoids, corticosterone, adipose tissue, transgenic mice, insulin resistance, diabetes mellitus, hyperlipidemia, hyperphagia, leptin, high-fat diet
- MeSH terms
- Abdomen, Adipose Tissue, Animals, Body Composition, Corticosterone, Dietary Fats, Disease Models, Animal, Eating, Humans, Hydroxysteroid Dehydrogenases, Hyperglycemia, Hyperinsulinism, Insulin Resistance, Lipids, Lipoprotein Lipase, Male, Mice, Transgenic, Obesity, Receptors, Glucocorticoid, Viscera, Weight Gain, Adipocytes, Gene Targeting, Leptin, Metabolic Syndrome, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Cell Size, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.